Repligen Licenses Potential Treatment for Spinal Muscular Atrophy Conference Call  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Oct 23 Calls Today's Calls

Call Details Repligen Licenses Potential Treatment for Spinal Muscular Atrophy Conference Call Fri, Oct 23, 2009, 8:30 am Eastern Listen to the archived event audio About Repligen Corporation (NasdaqGM:RGEN) Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company’s development stage products include RG1068, human secretin for improved MRI of the pancreas; and transcription enhancers for Friedreich’s ataxia caused by a single gene defect that results in inadequate production of the protein frataxin, and Huntington’s disease. Its development stage products also include RG2417; Uridine for bipolar depression; and a biological compound for multiple biosynthetic processes, including the synthesis of DNA and RNA, and various other factors essential for cell metabolism. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings